## **Product** Data Sheet

## Sertindole-d4

Molecular Formula:

 Cat. No.:
 HY-14543S

 CAS No.:
 1794737-42-0

Molecular Weight: 444.97

Target: 5-HT Receptor; Dopamine Receptor; Autophagy; Adrenergic Receptor; Isotope-

**Labeled Compounds** 

 $C_{24}H_{22}D_4CIFN_4O$ 

**Pathway:** GPCR/G Protein; Neuronal Signaling; Autophagy; Others

Storage: 4°C, sealed storage, away from moisture and light

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture

and light)

## **BIOLOGICAL ACTIVITY**

Description	Sertindole- $d_4$ is the deuterium labeled Sertindole. Sertindole, a neuroleptic, is one of the newer antipsychotic medications available [1][2].
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Juruena, M.F., E.P. de Sena, and I.R. de Oliveira, Sertindole in the management of schizophrenia. J Cent Nerv Syst Dis, 2011. 3: p. 75-85.

[3]. Kane, J.M. and C.A. Tamminga, Sertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic. Expert Opin Investig Drugs, 1997. 6(11): p. 1729-41.

[4]. Murdoch, D. and G.M. Keating, Sertindole: a review of its use in schizophrenia. CNS Drugs, 2006. 20(3): p. 233-55.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA